California Public Employees Retirement System increased its stake in shares of XOMA Corp (NASDAQ:XOMA) by 11.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 11,860 shares of the biotechnology company’s stock after acquiring an additional 1,220 shares during the period. California Public Employees Retirement System owned 0.14% of XOMA worth $150,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in XOMA by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 311,093 shares of the biotechnology company’s stock valued at $5,466,000 after buying an additional 3,167 shares during the last quarter. Vanguard Group Inc lifted its position in shares of XOMA by 1.0% in the 3rd quarter. Vanguard Group Inc now owns 311,093 shares of the biotechnology company’s stock worth $5,466,000 after acquiring an additional 3,167 shares during the period. BlackRock Inc. lifted its position in shares of XOMA by 0.8% in the 3rd quarter. BlackRock Inc. now owns 452,542 shares of the biotechnology company’s stock worth $7,951,000 after acquiring an additional 3,686 shares during the period. Bank of New York Mellon Corp lifted its position in shares of XOMA by 41.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 50,560 shares of the biotechnology company’s stock worth $888,000 after acquiring an additional 14,899 shares during the period. Finally, Jefferies Group LLC bought a new stake in shares of XOMA in the 3rd quarter worth approximately $313,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have commented on XOMA shares. Zacks Investment Research upgraded XOMA from a “sell” rating to a “hold” rating in a research report on Saturday, March 9th. Wedbush reiterated a “buy” rating and issued a $26.00 price objective on shares of XOMA in a research report on Monday, March 11th. ValuEngine upgraded XOMA from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. Finally, HC Wainwright set a $30.00 target price on XOMA and gave the stock a “buy” rating in a research report on Friday, April 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $24.82.
XOMA (NASDAQ:XOMA) last issued its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.14. XOMA had a negative return on equity of 175.48% and a negative net margin of 251.80%. The firm had revenue of $1.69 million during the quarter, compared to the consensus estimate of $1.30 million. As a group, research analysts predict that XOMA Corp will post -1.41 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “California Public Employees Retirement System Raises Stake in XOMA Corp (XOMA)” was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/05/04/california-public-employees-retirement-system-has-150000-holdings-in-xoma-corp-xoma.html.
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.
Featured Article: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.